ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
2,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
3,1,Coronary artery occlusion,Coronary artery disorders NEC,Coronary artery disorders,Card,N
3,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
4,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
4,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
4,4,Pulmonary congestion,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
5,1,Acute interstitial pneumonitis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
6,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
6,2,EGFR gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
6,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
6,4,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
6,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
7,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
7,2,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
7,3,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
7,4,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
8,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
8,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,3,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
9,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
9,2,Ventricular fibrillation,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
9,3,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
10,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
10,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
11,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
12,1,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
12,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
13,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
13,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
13,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
14,1,Gastrointestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
14,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
15,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
15,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
16,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
16,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
16,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
17,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
18,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
18,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
18,3,Retroperitoneal fibrosis,Peritoneal and retroperitoneal fibrosis and adhesions,Peritoneal and retroperitoneal conditions,Gastr,N
18,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
19,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,Y
19,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
20,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
21,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
21,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
22,1,Ingrowing nail,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
22,2,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
23,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
23,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
23,3,Tumour hyperprogression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
24,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
24,2,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
24,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
25,1,Status epilepticus,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
26,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
27,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
28,1,Keratitis,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
29,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
29,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
29,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
29,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
29,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
29,6,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
29,7,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
29,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
29,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
30,1,Osteonecrosis of jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
31,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
31,2,Meningeal disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
31,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
32,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
32,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
32,3,Malignant transformation,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
32,4,Superior vena cava occlusion,Site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
33,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
33,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
33,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
34,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
34,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,1,Cardiac flutter,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
35,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
36,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
36,2,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
36,3,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
36,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
36,5,Ventricular extrasystoles,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
37,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
37,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
38,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
38,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
38,3,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
38,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
38,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
38,6,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
38,7,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
38,8,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
38,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
38,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
38,11,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
39,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
39,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
39,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
40,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
41,1,Metastases to bone marrow,Metastases to specified sites,Metastases,Neopl,N
41,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
41,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
42,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
43,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
44,1,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
44,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
44,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
44,4,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
45,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
46,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
47,1,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
48,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
48,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
48,3,Immune-mediated lung disease,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
48,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
48,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
48,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
48,7,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
48,8,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
49,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
49,2,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
49,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,4,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
49,5,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
49,6,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
49,7,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
49,8,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
50,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
51,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
51,2,Eructation,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
51,3,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
51,4,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
52,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
53,1,Hair texture abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
53,2,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
54,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
55,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
55,2,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
55,3,Premature menopause,Menopausal effects NEC,Menopause related conditions,Repro,N
56,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
57,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
57,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
57,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
57,4,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
58,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
59,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
59,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
59,3,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,Y
60,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
61,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
62,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
62,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
63,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
64,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
64,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
64,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
65,1,Fluid intake reduced,Fluid intake decreased,Electrolyte and fluid balance conditions,Metab,N
65,2,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
65,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
65,4,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
65,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
65,6,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
66,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
67,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
67,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
68,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
68,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
68,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
68,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
68,5,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,Y
69,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
69,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
69,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
69,4,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
69,5,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
69,6,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
70,1,Hair growth abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
71,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
72,1,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,Y
73,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
73,2,Product residue present,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
74,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
75,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
76,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
76,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
76,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
77,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
78,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
79,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
80,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
81,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
81,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
82,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
83,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
84,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
84,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
85,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
86,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
87,1,Headache,Headaches NEC,Headaches,Nerv,N
87,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
88,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
89,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
90,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
91,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
91,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
91,3,Paronychia,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
92,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
93,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
93,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
94,1,Abdominal adhesions,Peritoneal and retroperitoneal fibrosis and adhesions,Peritoneal and retroperitoneal conditions,Gastr,N
95,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
96,1,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
96,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
96,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
96,4,Metastases to meninges,Metastases to specified sites,Metastases,Neopl,Y
96,5,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
97,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
97,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
98,1,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
99,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
100,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
101,1,Cryoglobulinaemia,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
101,2,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
102,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
102,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
102,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
103,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
104,1,Nephritis,Nephritis NEC,Nephropathies,Renal,N
105,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
105,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
106,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
106,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
107,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
108,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
109,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
109,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
110,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
111,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
112,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
113,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
114,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
115,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
116,1,Acquired gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
116,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
116,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
117,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
118,1,Blood alkaline phosphatase abnormal,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
119,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
119,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
119,3,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
120,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
121,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
121,2,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
122,1,Blood creatinine decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
122,2,Blood uric acid decreased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
122,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
122,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
122,5,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
123,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
124,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
124,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
124,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
124,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
124,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
125,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
125,2,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
125,3,Heart failure with reduced ejection fraction,Left ventricular failures,Heart failures,Card,Y
125,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
126,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
127,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
128,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
129,1,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
130,1,Heart rate,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
131,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
132,1,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
132,2,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
132,3,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
132,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
132,5,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
132,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
132,7,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
133,1,Blood sodium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
133,2,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
133,3,Lymphopenia,Leukopenias NEC,White blood cell disorders,Blood,N
134,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
135,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
136,1,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
136,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
136,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
136,4,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
136,5,Renal cyst,Renal neoplasms,Renal disorders (excl nephropathies),Renal,N
136,6,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
137,1,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
137,2,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
138,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
138,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
139,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
139,2,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
140,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
141,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
142,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
142,2,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
142,3,Uterine leiomyoma,Uterine neoplasms benign,Reproductive neoplasms female benign,Neopl,N
143,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
144,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
145,1,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
145,2,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
145,3,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
145,4,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
146,1,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
147,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
148,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
149,1,Acquired gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
149,2,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
149,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
149,4,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
149,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
149,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
149,7,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
149,8,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
149,9,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
150,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
150,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
150,3,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
151,1,Acquired gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
151,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
152,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
153,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
154,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
154,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
155,1,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
156,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
157,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
158,1,EGFR gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
158,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
158,3,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
158,4,TP53 gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
159,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
160,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
161,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
162,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
163,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
164,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
164,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
164,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
164,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
164,5,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
164,6,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
164,7,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
164,8,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
164,9,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
164,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
165,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
165,2,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
165,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
165,4,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
165,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
166,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
166,2,Onychomalacia,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
167,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
168,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
169,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
170,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
171,1,Acne,Acnes,Skin appendage conditions,Skin,N
171,2,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
171,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
172,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
172,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
172,3,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
173,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
174,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
174,2,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
175,1,Paronychia,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
175,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
176,1,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
177,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
178,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
179,1,Gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
179,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
180,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
181,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
182,1,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
183,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
184,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
184,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
184,3,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
185,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
185,2,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
186,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
186,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
186,3,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
187,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
188,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
189,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
190,1,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
190,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
190,3,Suspected counterfeit product,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
191,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
192,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
192,2,Metastases to breast,Metastases to specified sites,Metastases,Neopl,N
192,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
193,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,Y
194,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
194,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
194,3,Dilated cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
194,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
194,5,Malignant neoplasm oligoprogression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
194,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
194,7,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
194,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
195,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
